February 2009

Clinical Trials: Urologic Oncology

UNC Lineberger's clinical trial, LCCC O521, is a Phase II Study of Erlotinib (Tarceva) in Patients with Muscle-Invasive Bladder Cancer Undergoing Radical Cystectomy.

The trial seeks to improve cancer outcomes in patients with invasive bladder cancer utilizing novel oral targeted therapies. These therapies hold the potential and promise of increased efficacy over surgery alone and have relatively less side effects than conventional chemotherapy regimens. Photo credit: stock.xchng.com.

 

A partial list of priority urologic oncology clinical trials at UNC follows below.

 

LCCC 0603: A Pilot Neoadjuvant Clinical Trial with Evaluation of Molecular Effects with Sorafenib for Patients with Stage II or Greater Renal Cell Carcinoma.

PI: Kimryn Rathmell, MD, 919-966-8644

Study Coordinator: Gayle Grigson, RN, OCN, 919-966-4432, (toll free) 1-877-668-0683

LCCC 0521 (featured above): A Phase II Study of Erlotinib (Tarceva) in Patients with Muscle-Invasive Bladder Cancer Undergoing Radical Cystectomy

PI: Raj Pruthi, MD, 919-966-2574

Study Coordinator: Gayle Grigson, RN, OCN, 919-966-4432, (toll free) 1-877-668-0683

EFC 6668: Randomized Study of LAROTAXEL + Cisplatin (LC) vs. Gemcitabine + Cisplatin (GC) in the First Line Treatment of Locally Advanced /Metastatic Urothelial Tract or Bladder Cancer

PI: Kimryn Rathmell, MD, 919-966-8644

Study Coordinator: Gayle Grigson, RN, OCN, 919-966-4432, (toll free) 1-877-668-0683

CHIC 001 (featured on right): An Exploratory Study Evaluating FDG-PET as a Predictive Marker For mTOR Directed Therapy with RAD 001 in Metastatic Renal Cell Cancer

PI: Kimryn Rathmell, MD, 919-966-8644

Study Coordinator: Gayle Grigson, RN, OCN, 919-966-4432, (toll free) 1-877-668-0683

H8K-MC-JZAI (opening to accrual soon): A trial for metastatic renal cell cancer using a new Lilly drug in combination with Sutent

PI: Kimryn Rathmell, MD, 919-966-8644

Study Coordinator: Gayle Grigson, RN, OCN, 919-966-4432, (toll free) 1-877-668-0683

More Urologic Oncology Clinical Trials at UNC

UNC Urologic Oncology Program

As part of Carolina Well, UNC Lineberger's Cancer Survivorship Program, a pilot testicular survivors cancer clinic is currently available. It meets the 3rd Thursday of each month. The survivorship clinic includes a treatment summary, a care plan, and coordination with primary doctors. The clinic also serves as a referral resource for any ongoing problems and concerns.

Carolina Well is a member of the LIVESTRONG Survivorship Center of Excellence Network. The program aims to improve survivorship for all cancer patients and plans to develop more services and programs for patients who have completed active treatment. Carolina Pointe II - a facility dedicated to survivorship programs - is scheduled to open in the spring of this year. It will be located at Highway 54 and 40.

Pictured above are (from L - R) Dr. Paul Godley, Co-Principal Investigator, Nathan Ladd, a participant in the survivorship clinic for testicular cancer patients, and Liz Sherwood, Survivorship Clinic Coordinator. Read Nathan's story.

 

Other Highlights